NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026.
Updated guidelines consolidate evidence on myelofibrosis management from 32 leading specialists, guiding treatment decisions across practice.
The NCCN MPN Guidelines version 2.2026 represents the latest evidence synthesis and expert consensus from 32 specialists at major US cancer centres, focusing specifically on updated myelofibrosis management recommendations including JAK inhibitor use, high-risk disease definitions, and new therapeutic options. This is the primary clinical reference document for MPN management across US and internationally recognised oncology practice.
What the study was
- Study design
- clinical_guideline
- Category
- hematologic_malignancies
- Maturity
- Validated
- Journal
- J Natl Compr Canc Netw
Why it surfaced
JNCCN; immediately referenced in daily clinical decision-making for MPN; novelty capped at 1 as guideline update not primary research; high clinical_applicability as directly shapes treatment decisions for tens of thousands of MPN patients; myelofibrosis updates most clinically impactful section.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.